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Androgens are mainly prescribed to treat several diseases caused by testosterone
deficiency. However, athletes try to promote muscle growth by manipulating testosterone
levels or assuming androgen anabolic steroids (AAS). These substances were originally
synthesized to obtain anabolic effects greater than testosterone. Although AAS are rarely
prescribed compared to testosterone, their off-label utilization is very wide. Furthermore,
combinations of different steroids and doses generally higher than those used in
therapy are common. Symptoms of the chronic use of supra-therapeutic doses of
AAS include anxiety, depression, aggression, paranoia, distractibility, confusion, amnesia.
Interestingly, some studies have shown that AAS elicited electroencephalographic
changes similar to those observed with amphetamine abuse. The frequency of side
effects is higher among AAS abusers, with psychiatric complications such as labile mood,
lack of impulse control and high violence. On the other hand, AAS addiction studies are
complex because data collection is very difficult due to the subjects’ reticence and can
be biased by many variables, including physical exercise, that alter the reward system.
Moreover, it has been reported that AAS may imbalance neurotransmitter systems
involved in the reward process, leading to increased sensitivity toward opioid narcotics
and central stimulants. The goal of this article is to review the literature on steroid abuse
and changes to the reward system in preclinical and clinical studies.
Keywords: anabolic androgenic steroid, reward, dopamine, serotonin, psychosis spectrum disorders, depression
Introduction
Anabolic-androgenic steroids (AAS) are synthetic compounds derived from testosterone, which
is the main male hormone. The binding of testosterone to androgen receptors has anabolic and
androgenic effects. During puberty, the increase in testosterone levels contributes to linear growth
augmentation, as well as muscle mass accumulation (Bhasin et al., 1996, 2001; Brower, 2002;
Kuhn, 2002) by inducing hypertrophy without changes in the absolute number of both Type 1
and 2 muscle fibers (Sinha-Hikim et al., 2002). Testosterone also acts by increasing the number of
muscle progenitor cells (Sinha-Hikim et al., 2003) and promoting their myogenic differentiation
(Singh et al., 2003, 2006). Testosterone promotes mitochondrial biogenesis, improves net oxygen
delivery to the tissue by increasing red cell mass and tissue capillarity, and facilitates oxygen
unloading from oxyhemoglobin (Coviello et al., 2008; Gupta et al., 2008). The idea of designing and
developing steroids with anabolic properties arose during the 1930s soon after the identification
and isolation of the hormone androsterone by the German investigator Butenandt, who collected
this compound from thousands of liters of pooled human urine derived from a number of
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military service volunteers. Most of the AAS used before the
1990s were pharmacological agents approved for medicinal
or veterinary use. By the 1990s, various androgen precursors
became nutritional supplements. Androgen precursors are either
inactive or weak androgens that the body converts into
potent androgens. These include naturally occurring precursors
to testosterone, such as 4-androstenediol, 5-androstenediol,
4-androstenedione, and dehydroepiandrosterone, as well as
precursors to synthetic AAS including 4-norandrostenedione,
4-norandrostenediol, and 5-norandrostenediol, which the body
converts to nandrolone (Pope et al., 2014). Other synthetic
AAS, such as 17-desmethylstanozolol, methylclostebol, and
methyltrienolone have been recently introduced into the market
as dietary supplements. These “designed” steroids have not
undergone toxicological or safety testing in humans or animals.
Thus, they potentially represent an even more serious health risk
than the more traditionally used AAS.
Medical Use
From a clinical standpoint, AAS are commonly prescribed
to treat several disorders, such as the androgen deficiency
syndromes (Conway et al., 2000), hereditary angioedema,
hematological disorders (Shahidi, 2001), catabolic conditions,
such as some types of cancer-related cachexia (Langer et al.,
2001), metabolic dysfunctions induced by severe burn (Hart et al.,
2001), inflammatory pulmonary diseases (Ferreira et al., 2001),
radiation therapy, and AIDS-associated malnutrition (Basaria
et al., 2001; Polsky et al., 2001). Less common medical uses
of AAS deal with heart and renal failure (Basaria et al., 2001).
Contrasting data exists in the literature regarding the use of
AAS in the treatment of androgen deficiency in aging males,
infertility, sexual dysfunctions or impotence, as well as post-
menopausal syndrome in women. Thus, while a review of
Morley (2001) points toward therapeutic effects on libido and
menopause-induced sarcopenia, Conway et al. (2000) consider
their therapeutic application in these pathological conditions as
≪misuse of androgens≫. Hence, according to the state of the
art presented in their review, they reported no indication for
androgen therapy in male infertility because of its suppressing
effect on spermatogenesis. Importantly, there is no evidence in
available literature that AAS abuse or dependence might develop
from the legitimate medical use of AAS.
Non-medical Use
The use of AAS for non-medical intentions can easily
determine abuse and lead to dependence. When used by
athletes, AAS can improve performance to levels obtainable
by virtually any other combination of non-chemical solutions
provided by modern sport techniques (Noakes, 2004). Generally,
supra-pharmacological doses of AAS act either by a direct
mechanism, promoting an increase in mass, force, speed
of muscular contraction, and recovery after intense physical
exercise (Tremblay et al., 2004) or by an indirect pathway through
erythropoietic stimulation, leading to increased synthesis of
2,3-diphospholglycerate and tissutal oxygen transfer facilitation
(Shahidi, 2001). Consumption of high doses of AAS typically
consists in 6–12 week cycles, followed by a 6–12 week period
of wash-out. These patterns of AAS use may easily precipitate
in periods of continuous consumption without any AAS-free
intervals due to the fact that abusers try to assure their muscle
gains while avoiding withdrawal symptoms (Brower, 2002; Kuhn,
2002). Several other drugs are frequently associated with the
use of supra-pharmacological doses of AAS by abusers that are
designed to increase their effects, diminish side effects or avoid
detection by urine testing (Wichstrom and Pedersen, 2001). The
abuse of other illicit drugs, such as amphetamines and opioids,
has also been shown to be strengthened by AAS use (Arvary
and Pope, 2000). Moreover, such abuse might reinforce the
occurrence of adverse substance interactions. In particular, in
the case of AAS and amphetamine association, the overdose
potential appears to be increased, due to cardiotoxicity (Thiblin
et al., 2000). The contemporary consumption of AAS and
bromocriptine, used to rapidly reduce body fat and total weight,
has been described as the cause of a syndrome characterized by
syncopal episodes and atrial fibrillation (Manoharan et al., 2002).
Populations of adolescents and young adults have been the
subject of several clinical studies that explore the prevalence
of AAS misuse and abuse. Irving et al. (2002) conducted a
study on a population of 4746 middle and high school students
from public schools of Minneapolis completing surveys and
anthropometric measurements as part of a population-based
study of eating patterns and weight concerns among teenagers
(Project EAT: Eating Among Teens). They observed that steroid
use was more common in non-Caucasian males and in middle
school students as compared to high school. In males, steroid use
was associated with poor self-esteem, higher rates of depressed
mood and attempted suicide, poor knowledge and attitudes
about health, greater participation in sports emphasizing weight
and shape, greater parental concern about weight, and higher
rates of eating disorders and substance abuse. In a study by
Wichstrom and Pedersen (2001), a representative sample of 8877
Norwegian youths (15–22 years of age) was surveyed. Results
showed that AAS use did not vary according to sport involvement
or demographics. Moreover, AAS use was associated mainly with
the abuse of marijuana, aggressive-type conduct problems and
eating disorders.
Adverse Effects
The severity and impact of side effects induced by AAS abuse
depend on a wide range of factors, such as dose, duration of
administration, possible consumption of a combination of AAS,
as well as gender and age of the abusers. Data on the impact of
sustained administration, failed to show any documented adverse
events associated to a single episode of acute consumption
of supra-pharmacological doses of AAS. Their abuse has been
shown to be associated to greater effects on physical performance
in younger individuals and women, together with increased
incidence and risk of developing serious side events (Kindlundh
et al., 1999). Few data exist on the risk of side effects linked to
long-term use of high-dose of AAS for non-therapeutic purposes
(Parssinen and Seppala, 2002). Cardiovascular complications
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have been widely described in AAS abusers, including the
occurrence of arrhythmic events (Furlanello et al., 2003). In
a recent post-mortem study that compared 87 deceased men
positive for AAS with 173 control subjects (Far et al., 2012), AAS
users showed significantly greater cardiac mass.
In another clinical investigation, ventricular hypertrophy,
associated with fibrosis and myocytolysis, was detected after
cardiac death in four AAS users (Montisci et al., 2012).
Also, controlled studies realized by echocardiography (Krieg
et al., 2007; Hassan et al., 2009; Baggish et al., 2010) or by
cardiac magnetic resonance imaging (Luijkx et al., 2013) have
demonstrated lower ventricular ejection fractions and reduced
diastolic tissue velocities in AAS users.
Pathological effects on urogenital and reproductive
systems have been reported. In particular, hypogonadotropic
hypogonadism with consequent testicular atrophy in men
and development of inhibitory mechanisms for FSH and
LH production in women have been described in selected
populations of AAS abusers (Anderson and Wu, 1996; Dohle
et al., 2003). Increased virility and lowering of voice tone,
irregular menstruation with infertility, decreased breast size,
hypertrophic clitoris, and increased sexual desire have also been
described in a population of female AAS abusers (Franke and
Berendonk, 1997; Kutscher et al., 2002). Other complications
include liver damage and hepatitis (Tanaka et al., 2000), insulin-
resistance secondary to glucose intolerance with alterations
of thyroid function (Yesalis et al., 2000), increased risk of
infectious diseases caused by inappropriate use of syringes and
non-protected sexual relations among AAS users (Aitken et al.,
2002). Although several studies point toward a reversibility of
undesirable AAS-induced effects following suspension, they can
become irreversible complications with prolonged AAS abuse
(Kutscher et al., 2002).
Psychiatric Effects
AAS are universally recognized to have psychoactive effects
(Yates, 2000). Although some spared studies have reported their
therapeutic use in depression to improve mood and anergia
(Rabkin et al., 2000), most evidence points toward the association
of AAS with depression, mania, psychosis, suicide and increased
aggression leading to violence and, in extreme cases, to homicide
(Pope and Brower, 2000; Pope et al., 2000; Thiblin et al., 2000).
Indeed, suicide and homicide have been shown to be the main
cause of premature deaths among steroid users and, in particular,
in the teen population (Thiblin et al., 1999b). Although this does
not imply that all steroid users will suffer crippling depression
or homicidal rage, steroids appear to strongly contribute to
psychiatric dysfunctions in susceptible individuals.
Globally, the prevalence of AAS-induced psychiatric disorders
has been hard to evaluate and determine, because of sampling
biases in clinical case reports. In a review of Pope et al., (Pope
et al., 2000), summarizing four prospective, placebo-controlled
trials, it has been reported that at least 5% of AAS users will
experience AAS dose-dependent maniac or hypomaniac episodes
(Pope and Brower, 2000). However, this estimated percentage
appears to be influenced by the fact that in most controlled
trials, it is not possible to completely mimic the extreme doses
and combinations of AAS taken by abusers for ethical reasons.
Thus, estimated rates of AAS-induced psychiatric alterations are
probably even higher. This is also due to the fact that other
factors can increase the likelihood of psychiatric consequences
of AAS abuse, such as the presence of a positive psychiatric
anamnesis, alcohol, or other drug use (Dean, 2000) as well as
other medical comorbidities. For example, in a case-report of
Morton et al. (2000), the authors described the case of a man
suffering from Axis II psychopathology, who developed severe
psychosis after receiving therapeutic doses of an anabolic steroid
for burn injuries in combination with lorazepam and opioids.
Psychological motivations contributing to anabolic steroid use
and abuse have received little attention in psychiatric literature.
Clinical studies demonstrate that steroids are used in part to deal
with an earlier trauma, such as childhood physical or sexual abuse
(Porcerelli and Sandler, 1995).
Effects on the Brain Reward Function:
Dependence and Addiction Potential
The data in the literature show no documented cases of
dependence induced by AAS use at therapeutic doses. This
suggests that dependence is likely associated to the use of higher
doses of AAS (Long et al., 2000; Thiblin et al., 2000; Haupt,
2001; Brower, 2002; Kutscher et al., 2002); Figure 1 graphically
represents this hypothesis. However, molecular mechanisms
leading to AAS-induced dependence are still unclear.
In a review of the scientific literature published between 1988
and 1998 (Brower, 2000), AAS dependence was defined as a
diagnosable mental disorder. Between 1999 and 2000, two more
diagnostic studies of AAS dependence were published (Midgley
et al., 1999; Brower, 2000).
A “withdrawal syndrome” induced by AAS abuse has been
clearly described, consisting mainly of depressed mood, fatigue,
AAS craving, restlessness, anorexia, insomnia, and decreased
FIGURE 1 | Main clinical observations linking AAS consumption to AAS
addiction.
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libido lasting for several weeks or months (Brower, 1997, 2000).
In the 1980s, Tennant et al. (1988) described a case report on
which a model of a biphasic course of withdrawal was proposed.
The initial phase of the AAS-induced withdrawal (lasting for
about 1 week) seemed to be comparable to opioid-induced
withdrawal, while the second phase was mostly characterized by
clear depressive symptoms and craving (Tennant et al., 1988).
Considerable evidence suggests that AAS dependence might
share crucial mechanisms of opioid dependence in humans. In
1989, Kashkin and Kleber (1989) posited that AAS dependence
might partly arise via an opioidergic mechanism, through which
AAS might enhance the activity of central endogenous opioids,
and AAS withdrawal would lead to a decrease in this activity
and a subsequent acute hyperadrenergic syndrome (Kashkin and
Kleber, 1989). This posited link between AAS and opioids was
later confirmed by a large number of observations indicating that
AAS users seem to be particularly at risk for developing opioid
abuse or dependence (McBride et al., 1996; Wines et al., 1999).
Additional clinical studies provided evidence that AAS might
decrease the analgesic action of both metamizol and morphine
(Philipova et al., 2003).
In 2009, a study by Kanayama et al. (2009) added further
evidence for a relationship between AAS and opioids. In the
population included in that study, opioid abuse or dependence
began either before or after the onset of AAS use, suggesting the
possibility that these forms of substance abuse might arise from
a commonmolecular pathway (Kanayama et al., 2009). However,
in a study of Negus et al. (2001), authors could not detect any
withdrawal phenomena following administration of high doses
of AAS (Negus et al., 2001).
AAS seem to act through a more modest reinforcement
mechanism compared to cocaine or heroin and resembles
the reinforcement mechanism described for caffeine, nicotine,
and benzodiazepines. In 2002, Brower (2002) proposed a
2-stage model of steroid dependence. In Stage 1, anabolic
effects of AAS provide the initial input and motivation for
AAS consumption. Stage 2 deals with consequent chronic use,
following which physiological and psychological dependence
may develop, thereby making it increasingly difficult for users to
quit. Psychoactive effects, such as mood changes and increases
in aggressive behavior, characterize this stage of dependence.
Diagnostic and Statistical Manual of Mental Disorders criteria
for AAS dependence are met and users are not able to stop or
discontinue AAS consumption. In Stage 2, addiction treatment
may be required, especially when AAS abuse is associated
with other substance dependence, such as alcohol, opioids, or
amphetamine abuse (Brower, 2002). Arvary and Pope (2000)
investigated this phenomenon in a clinical study, including 227
patients admitted to a private facility for dependence on heroin
or other opioids. Results of this study strongly suggested that
these patients were introduced to opioids through AAS use and
bodybuilding physical activity. In particular, 81% of them first
purchased opioids from the same drug dealer who had sold them
AAS; 67% were introduced to opioids by a fellow body-builder;
86% first used opioids to reduce insomnia and irritability induced
by AAS, and 67% used opioids to diminish depression feelings
induced by withdrawal from AAS (Arvary and Pope, 2000).
A second model, explaining mechanisms leading to AAS
dependence, has also been proposed (Bahrke and Yesalis,
1994). This model holds that AAS-dependence development
occurs specifically in socio-cultural contexts that are likely to
motivate certain individuals, particularly men, to attain large
and strong muscles by frequent and intensive training sessions.
These training sessions also improve mood and self-esteem
and are generally associated with very strict and controlled
dietary regimens. Thus, AAS-inducedmuscle-active effectsmight
underlie the reinforcing actions of these compounds (Midgley
et al., 1999) and the compulsive features of AAS use seem to
strengthen the likely compulsive patterns of training and diet.
Studies to elucidate mechanisms leading to AAS dependence
have also included surveys of current and former AAS users,
recruited from gyms, websites, and physicians. Brower et al.
(1990) reported numerous criteria for psychoactive substance
dependence in a survey of eight AAS abusers, including
continued use despite adverse side effects, and withdrawal
symptoms (Brower et al., 1990).
Specific dysfunctions of the various components of the
brain reward system have been described in clinical studies.
For example, alterations in levels of monoamine metabolites,
neurohormones, and neuropeptides, which play a crucial
role in the reward mechanism, have been investigated in the
cerebrospinal fluid of subjects who received methyltestosterone
(MT) with respect to placebo-treatment (Daly et al., 2001).
Results showed that levels of 5-hydroxyindolacetic acid
(5-HIAA) increased while 3-metoxy-4-hydroxyphenylglycol
(MHPG) levels decreased in cerebrospinal fluid, following MT
administration. In particular, changes in cerebrospinal fluid
5-HIAA significantly correlated with the activation of specific
psychiatric symptom cluster scores. In addition, according to
this study, a decrease in cerebrospinal fluid MHPG may derive
from reduced norepinephrine clearance, even though authors
did not detect any significant correlations between changes
in MHPG levels and the development of clear psychiatric
symptoms, suggesting a less crucial role for noradrenergic
changes in this process. An increase in substance P levels and
vasopressin (Hallberg et al., 2000; Harrison et al., 2000), as well
as dysfunctions of the central opioid system (Schlussman et al.,
2000), have been proposed as playing a potential role in the
development of aggressive behavior after AAS abuse.
Multiple factors have been associated with the induction of
dependence in AAS users, such as low endogenous levels of
testosterone. Indeed, it has been demonstrated that women,
adolescents and elderly subjects have a lower probability of
developing AAS dependence (Wood et al., 2004). Among
possible risk factors for dependence development, the most
relevant appears to be participation in competitive sports
with intense and repetitive physical exercise (Kanayama et al.,
2003b). Some investigators have also suggested that personality
psychopathology may be a risk factor for AAS abuse. Yates et al.
(1990) reported that AAS users and weight lifters had a higher
prevalence of histrionic, antisocial, and borderline personality
traits than community controls. Although a growing number
of reports, current knowledge of molecular mechanisms leading
to AAS dependence in humans remains limited. In this regard,
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the reinforcing effects of AAS may also be biased by intensive
physical exercise and by increased narcissistic self-esteem arising
from the fulfillment of the desired body appearance. On the other
hand, many users practice “stacking” consumption, consisting in
the contemporary mixed use of multiple steroids.
Since it has been reported that around 96% of users combine
AAS with other drugs in order to relieve non-medical steroid
side effects (Parkinson and Evans, 2006), pharmacodynamics,
and pharmacokinetic interaction studies are surely warranted,
although hardly feasible, in order to exclude further bias.
Behavioral and Neurochemical Responses
to AAS Administration in Animal Models
Preclinical studies have contributed in evaluating the impact
of AAS exposure on neurochemical mechanisms underlying
AAS-induced behavioral outcomes. Animal studies offer a direct
measure of behavioral parameters under conditions where age
and sex of the subjects, along with AAS administration, are
established by the investigator. In this section, we will focus
our attention on the data in the literature from animal models
employing different AAS exposure paradigms, frequently used
to model human abuse patterns. In particular, we will review
laboratory animal research findings to assess AAS-induced
behavioral effects, such as aggression and reward. Moreover, we
will highlight studies that have reported neuronal pathways and
signaling molecules involved in these behaviors.
Aggression
Behavioral human studies linking AAS abuse and aggression have
confounding factors, such as regimen (multiple steroids over a
cycle of use), co-administration with other drugs of abuse and
inaccurate measures of behavior simulated by subjective reports
(McGinnis, 2004). Conversely, experimental designs in animals
that correlate AAS exposure and aggression are less equivocal.
The resident-intruder test is a common paradigm for assessing
aggression. Initial studies on animal models have reported that
long-term exposure to high doses of testosterone raised levels of
aggression in gonadally intact rats and re-established aggression
in castrated rats (Lumia et al., 1994). However, indices of
aggressive responses depend on environmental context, social
cues, sex and hormonal status of the intruder, age of exposure,
physical provocation, and type of AAS administered (Clark and
Henderson, 2003; Lumia and McGinnis, 2010). Hence, studies
in rats showed that AAS-treated males demonstrated a different
predisposition for aggression when tested in three different
environments (home cage, opponent cage, or neutral cage)
(Christie and Barfield, 1979; Lumia et al., 1994; Breuer et al., 2001;
Farrell andMcGinnis, 2003). Adult male rats receiving high doses
of AAS are more aggressive toward the intruder in their home
cage and displayed lower levels of aggression in either opponents
or neutral cages (Breuer et al., 2001; Farrell and McGinnis,
2003). Investigators extended their interest to other experimental
factors demonstrating that AAS-treated rats are typically more
aggressive toward intact rather than castrated rats, as well as
toward ovariectomized rather than sexually receptive females
(Breuer et al., 2001; Farrell and McGinnis, 2003; Cunningham
and McGinnis, 2006, 2007). McGinnis et al. (2002a), showed that
12 weeks of testosterone propionate exposure enhanced inter-
male aggression in adult rats after physical provocation in the
form of a mild tail pinch. Moreover, the environmental and social
discriminating cues described above failed to alter testosterone-
induced aggressive responses to physical provocation (McGinnis
et al., 2002a,b). While testosterone clearly increases aggression,
conflicting results have been reported in the literature concerning
other commonly abused AAS (stanozolol, nandrolone decanoate,
boldenone undecylenate) tested either in combination or
individually. Salas-Ramirez et al. (2010) tested whether a 2-week
administration of an AAS cocktail containing testosterone
cypionate, nandrolone decanoate, and boldenone undecylenate
had dissimilar behavioral consequences when drug exposure
occurred during adolescence or adulthood. Higher aggression
levels were observed in male Syrian hamsters exposed to an
AAS cocktail compared to controls, regardless of age treatment
(Salas-Ramirez et al., 2010). On the other hand, stanozolol failed
to induce aggressive behavior in gonadectomized and intact
rats and mice (Clark and Barber, 1994; Martinez-Sanchis et al.,
1996; McGinnis et al., 2002a). More conflicting results have
been reported by using nandrolone decanoate. Long et al. (1996)
showed increased levels of aggression in Sprague–Dawley rats
receiving chronic nandrolone decanoate, while no effect has
been evidenced in Wistar rats (Zotti et al., 2014). Accordingly,
adult rats exposed to mild physical provocation demonstrated
decreased inter-male aggression when treated with stanozolol,
while no effects of nandrolone have been reported (Breuer
et al., 2001; Farrell and McGinnis, 2003). Regardless of the
experimental methodologies employed to assess aggression, these
findings suggest that strain, AAS chemical composition and
regimen reflect the diversity of supra-therapeutic AAS exposure
on behavioral responses in animals.
Several studies in preclinical models of aggression have
investigated the AAS effects on the neurochemical changes in
specific brain areas related to this behavior.
High aggression is often associated to decreased serotonin
(5-HT) neurotransmission. Although this may account for high
aggression as an individual feature, it has been suggested that
serotonergic activity is probably higher during performance of
aggressive behavior (van der Vegt et al., 2003).
In particular, testosterone propionate exposure decreased
both 5-HT and 5-HT metabolite, 5-HIAA, in the hippocampus
but not in the striatum or in the frontal cortex of adult rats
(Bonson et al., 1994). Moreover, the aggressive behavior of
dominant rats was decreased by treatment with selective agonists
of 5-HT1A, 5-HT1B, and 5-HT2A/2C receptors (Bonson et al.,
1994). A significant decrease in 5-HT1A and 5-HT1B receptors
immunoreactive staining has been shown in the latero-anterior
hypothalamus and amygdala of hamsters treated with a mixture
of AAS (Grimes and Melloni, 2005; Ricci et al., 2007). However,
no decrease in the number of 5-HT1A receptor-expressing
neurons and an increase in 5-HT2A receptor immunoreactivity
have been reported in the hypothalamus (Ricci et al., 2006;
Schwartzer et al., 2009). Ambar and Chiavegatto (2009) have
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reported reduced 5-HT1B mRNA levels in the hippocampus,
hypothalamus, amygdala, and prefrontal cortex of nandrolone-
treated mice suggesting that the serotonergic tone in these brain
areas has a pivotal role for AAS-induced aggression in rodents
(Ambar and Chiavegatto, 2009).
Reward
The data in literature highlight the potential for AAS addiction
in humans (Kashkin and Kleber, 1989; Brower et al., 1990,
1991; Brower, 2002; Wood, 2004). Nevertheless, it is difficult
to separate the direct rewarding effects of AAS from the
psychological dependence of users on their physical appearance,
muscular strength, and athletic performance. Hence, studies
in animal models are a useful tool when examining androgen-
reinforcing properties in conditions where anabolic effects
and athletic performance are not relevant. Conditioned
place preference (CPP) and self-administration are relevant
experimental paradigms used to study reward in an experimental
condition (Wood, 2004; Koob, 2006). Several studies in adult
rodents have reported that systemic testosterone injections
induced CPP in male rats and mice (de Beun et al., 1992;
Alexander et al., 1994; Arnedo et al., 2000, 2002; Frye et al.,
2001). In another animal model, it has been demonstrated that
15 days of administration of an AAS cocktail consisting of
testosterone cypionate, nandrolone decanoate, and boldenone
undecylenate, increased the rate of self-administration and
enhanced the sensitivity to amphetamine challenge (Clark et al.,
1996). However, in the same study, a 2 week treatment with
MT had no effect on reward or performance of intracranial
self-stimulation. In this light, Ballard and Wood (2005) have
reported that in animals drostanolone and nandrolone tend to
be self-administered (Ballard and Wood, 2005) and can cause
CPP (Frye et al., 2002). Moreover, such effects can be prevented
by dopaminergic antagonists (Schroeder and Packard, 2000)
indicating that dopaminergic pathways are necessary for these
behavioral outcomes. Indeed, the mesocorticolimbic circuitry,
such as nucleus accumbens (NAc) and ventral tegmental area
(VTA) are crucial for the reward system.
Parrilla-Carrero et al. (2009) investigated the rewarding
effects of three different types of synthetic androgens differing
in chemical structure and metabolism by using the CPP
test in adult mice. They found that systemic injection of
testosterone propionate and nandrolone decanoate, but not 17α-
methyltestosterone, produced a dose-dependent shift in CPP
suggesting that the rewarding properties of AASmight depend on
their interaction with different pathways (Parrilla-Carrero et al.,
2009). Very recently, the same research group has demonstrated
nandrolone’s failure to reward in adolescent mice (Martinez-
Rivera et al., 2015). Although the literature reports that the
adolescent brain is more sensitive to the reinforcing effects of
drugs of abuse, this study suggests that such sensitivity may be
drug dependent (Ernst et al., 2009; Galvan, 2010;Martinez-Rivera
et al., 2015).
Packard et al. (1997) reported that testosterone induced CPP
when directly injected into NAc (Packard et al., 1997). Similarly,
Frye et al. (2002) showed that direct implants of testosterone
or its metabolites (dihydrotestosterone, 3α-androstanediol) in
the NAc shell induced a preference for the androgen-associated
compartment, while no effect was observed with androgenic
stimulation of the NAc core, suggesting a sub-region-specific
functional role in reinforcement and reward pathway.
A growing body of evidence has shown the reinforcing
effects of AAS using the experimental self-administration (oral,
intravenous iv, intracerebroventricular icv) paradigm, which
is considered as a model of addiction with the greatest face
validity (Johnson andWood, 2001; Wood, 2004; Frye, 2007; Frye
et al., 2007). Wood (2002) demonstrated that gonadally intact
adult male hamsters preferentially self-administer testosterone
orally by using a food-induced drinking model (Wood, 2002).
Although oral self-administration resembles oral AAS intake
in humans, potential effects of taste solution or gut fill might
present an inherent limitation on AAS oral consumption.
Thus, Wood et al. (2004) used an operant chamber to
train animals with chronic jugular cannulae and demonstrated
an increase in testosterone iv self-administration compared
to controls. Moreover, Syrian hamsters voluntarily consume
testosterone through icv self-administration, suggesting that
testosterone-reinforcing effects are centrally mediated (DiMeo
and Wood, 2004; Wood, 2004). Ballard and Wood (2005)
extended their research study on androgens and compared icv
self-administration of four commonly abused AAS (nandrolone,
drostanolone, oxymetholone, stanozolol) that differ in their
method of administration, duration of action and metabolism.
Results from this study showed that male hamsters preferentially
self-administered nandrolone or drostanolone, which are two of
the mostly used injectable androgens in humans. Conversely,
animals failed to self-administer the orally active androgens
oxymetholone or stanozolol, suggesting that injectable androgens
may be more reinforcing than orally active steroids (Ballard and
Wood, 2005).
To better understand the behavioral outcomes described
above, various neurochemical studies have examined AAS effects
on the monoaminergic system by measuring neurotransmitter
and metabolite levels or by detecting receptors and enzyme
alterations in key brain areas linked to the reward pathway. It
has been reported that CPP induced by testosterone was blocked
when adult male rats were directly injected into NAc with a
D1-like or D2-like dopamine receptor antagonist (SCH23390
or sulpiride, respectively) (Schroeder and Packard, 2000). Sub-
chronic administration of high AAS doses reduced dopamine
D1-like receptor protein and mRNA levels in the NAc core and
shell and increased D4-receptor mRNA expression in NAc, while
D2-like receptors were up-regulated in the NAc core but down-
regulated in the shell (Kindlundh et al., 2001b, 2003; Birgner
et al., 2008a; Martinez-Rivera et al., 2015). An up-regulation of
the dopamine transporter (DAT) protein was observed in vivo
by a binding study using positron emission tomography (PET),
in the striatum of male rat brain after chronic treatment with
nandrolone (Kindlundh et al., 2002). Interestingly, Martinez-
Rivera et al. (2015), observed no difference of D1-receptor protein
expression in adolescent mice suggesting that the mesolimbic
dopaminergic system during adolescence is immature or not
sensitive to the rewarding response induced by nandrolone.
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Studies in Syrian hamsters suggested that testosterone reduced
dopamine (DA) release in NAc (Triemstra et al., 2008). Likewise,
our research group showed a reduction in DA content in NAc
of rats treated for 4 weeks with nandrolone, changes which were
accompanied by reduced hedonic-related behavior (Zotti et al.,
2014). Furthermore, Birgner et al. (2007), in a microdialysis
study, demonstrated that sub-chronic nandrolone decreased
extracellular levels of DA metabolites (DOPAC and HVA) in rat
NAc shell without affecting the release of DA. In line with these
results, nandrolone was shown to reduce type A and B activity
of monoamine oxidase (MAO) (Birgner et al., 2008b), although a
previous study reported no effects of the drug on these enzymes
activity in rats (Thiblin et al., 1999a). Further confirming the
role of dopaminergic system in AAS effects on reward pathway,
subchronic nandrolone has been shown to significantly down-
regulate D1 receptors in the NAc and caudate putamen of rats,
and to up-regulate D2-like receptors in the NAc core and VTA
(Kindlundh et al., 2001b). In this regard, D1 and D2 receptors
have been implicated in the reinforcing effects of drugs, as D1
is necessary for the acquisition of the effect and D2 crucial in
mediating positive reinforcement (Missale et al., 1998). On the
other hand, we have previously reported that stanozolol had
no effect on DA content in NAc (Tucci et al., 2012). Findings
regarding the impact of different AAS on brain reward function
are summarized in Table 1.
Contradictory neurochemical results have been reported
regarding AAS effects on the serotonergic system. In particular,
intranasal administration of testosterone has been shown
to increase dopaminergic and serotonergic systems in rat
neostriatum and NAc (de Souza Silva et al., 2009). Accordingly,
nandrolone decanoate and oxymethenolone treatment enhanced
5-HT and 5-HIAA concentrations in rat cerebral cortex and
hypothalamus, while decreased levels of 5-HT and 5-HIAA were
observed in the striatum of nandrolone-treated rats (Thiblin
et al., 1999a; Lindqvist et al., 2002; Tamaki et al., 2003). Moreover,
it has been shown that AAS affects 5-HT receptor expression.
In particular, sub-chronic nandrolone administration down-
regulates 5-HT1B and up-regulates 5-HT2 receptor density in
rat brain (Kindlundh et al., 2003). In addition, McQueen et al.
(1999) have demonstrated that serotonin transporter (SERT)
mRNA-expressing cells in the dorsal raphe nucleus, as well as the
density of SERT sites increase after sub-chronic treatment with
testosterone (McQueen et al., 1999).
On the other hand, several studies have associated the
endogenous opioid system to behaviors linked to reward
and reinforcement (Gianoulakis, 2009). Thus, a number of
experimental investigations have been carried out to ascertain
whether AAS treatment modifies the levels of opioid peptides
and their receptors in brain areas mediating reward. In particular,
β-endorphin levels have been reported to significantly increase
in the paraventricular thalamic nucleus and VTA of rats
treated with AAS cocktails or nandrolone decanoate, respectively
(Johansson et al., 1997; Harlan et al., 2000). In line with
previous reports, chronic exposure to nandrolone decanoate
has been linked to enhanced µ-, δ-, and κ-receptor binding in
the hypothalamus, striatum, and midbrain periaqueductal gray
(Johansson et al., 2000a). However, in the NAc shell and central
amygdala of rats treated with the higher dose of nandrolone
regimen, a down-regulation of κ-receptor binding, as measured
by autoradiography has been demonstrated (Magnusson et al.,
2009). Moreover, an increase in dynorphin converting enzyme-
like activity was found only in the NAc of rats exposed to chronic
nandrolone, suggesting an increased biosynthesis of dynorphin
peptides, which, in turn, might affect basal DA levels in the NAc
(Spanagel et al., 1992; Steiner and Gerfen, 1998; Magnusson et al.,
2007).
Other AAS Pathways and Reward
It is worth noting that AAS effects are commonly described
after chronic or sub-chronic drug exposure. Indeed, acute
subcutaneous testosterone administration failed to influence
accumbal DA release (Triemstra et al., 2008). In this regard,
it has been proposed that AAS effects on the reinforcement
system may be DA-independent, as happens with other abuse
substances such as ethanol and benzodiazepines. Moreover,
AAS effects on mesolimbic dopamine might be indirect or
rely on non-classic androgen-sensitive pathways. Thus, based
on accumulated evidence, AAS have an addictive potential,
especially in susceptible subjects.
As reported, many discrepancies need to be better clarified.
First, it is important to clarify whether classic nuclear receptors
are involved in these effects or if other mechanisms are also
involved. Moreover, scientific evidence exists for fast actions of
steroids acting on calcium channels, membrane receptors, second
messengers and membrane fluidity (for a review see Foradori
et al., 2008). In this regard, a recent in vitro study has shown
that testosterone, by acting on membrane receptors, was able to
increase hippocampal plasticity within 2 h, leading to increased
spine density (Li et al., 2015). Sato et al. (2010) investigated the
possible involvement of these types of receptors on reinforcement
effect of AAS. In particular, their experiments demonstrated that
animals, intact or carrying the testicular feminization mutation,
preferentially self-administer dihydrotestosterone (DHT) and
DHT conjugated to bovine serum albumin, DHT-BSA, which
acts only on cell surface. These observations prompted the
authors to conclude that androgen self-administration may be
mediated by plasma membrane receptors (Sato et al., 2010).
Accordingly, it has been postulated that classical genomic action
of androgen may be not fast enough to assure reinforcement.
In agreement to such hypothesis, the distribution of androgen
receptors in NAc and VTA is resulted quite sparse (Kritzer and
Creutz, 2008; Sato et al., 2008).
Nonetheless, it is worth to note that further signaling systems,
other than dopaminergic or opioidergic, can be implicated in
reward. Indeed, chronic nandrolone decanoate was found to
down-regulate the NR1 subunit of NMDA receptors in NAc of
treated rats (Le Greves et al., 1997). This finding led the Authors
to hypothesize that AAS may thus sensitize reward mechanisms.
However, the number of studies investigating the effects of
AAS on glutamatergic system in reward is still limited; hence,
future investigations should be focused accordingly to clarify
whether AAS reinforcement relies on non-classic pathways or on
other signaling systems.
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TABLE 1 | Preclinical overview of the impact of different AAS on reward system.
Drug Route and dose of administration Impact on reward system Species References
Testosterone 0.8–1.2mg/kg s.c ↑ CPP Mice Arnedo et al., 2000
1–2mg/kg s.c Arnedo et al., 2002
0.75mg/kg; 7.5mg/kg i.p Parrilla-Carrero et al., 2009
0.5–1mg/kg s.c ↑ self-administration Rats de Beun et al., 1992
0.8–1.2mg/kg s.c Alexander et al., 1994
1µg icv infusion, ↑ self-administration Hamsters Wood et al., 2004
50µg iv, DiMeo and Wood, 2004
1–4mg/ml oral self-administration Wood, 2002
2µg icv infusion ↓ DA (NAc) Hamsters Triemstra et al., 2008
Nandrolone 0.75mg/kg; ↑ CPP Adult Mice Parrilla-Carrero et al., 2009
7.5mg/kg i.p ↓ D1R (NAc) Martinez-Rivera et al., 2015
7.5mg/kg i.p No effect on CPP, no difference in D1R Adolescent Mice Martinez-Rivera et al., 2015
1µg/µl; 2µg/µl icv self-administration ↑ self-administration Hamsters Ballard and Wood, 2005
15mg/kg i.m ↑ DAT Rats Kindlundh et al., 2002
↓ D1R; ↓ D2R (NAc shell) Kindlundh et al., 2001b, 2003
↓ DOPAC, ↓ HVA Birgner et al., 2007
↓ MAO-A, ↓ MAO-B Birgner et al., 2008b
15mg/kg s.c ↓ DA (NAc) Rats Zotti et al., 2014
3mg/kg; 15mg/kg i.m ↑ D4R mRNA (NAc) Rats Birgner et al., 2008a
Stanozolol 1µg/µl; 2µg/µl icv self-administration No effect on self-administration Hamsters Ballard and Wood, 2005
15mg/kg s.c No effect on DA Rats Tucci et al., 2012
Methandrostenolone 1mg s.c No effect on intracranial self-stimulation Rats Clark et al., 1996
17α-methyltestosterone 0.75mg/kg; 7.5mg/kg i.p No effect on CPP Mice Parrilla-Carrero et al., 2009
AAS Effects on Other Drugs of Abuse
Clinical and epidemiological data have reported that the abuse of
AAS in humans is often associated with the abuse of psychotropic
drugs, such as cocaine, opiates, alcohol, cannabis, amphetamine,
and 3,4-methylenedioxy-methamphetamine (MDMA). These
surveys have suggested a role of AAS as a gateway to other
dependency-inducing drugs (DuRant et al., 1995; Arvary and
Pope, 2000; Kindlundh et al., 2001a; Kanayama et al., 2003a;
Thevis et al., 2008). Based on these findings, different animal
paradigms have been used to investigate AAS pre-exposure
effects on neurochemical and behavioral response to other
addictive substances. Consistent with reported higher alcohol
intake in AAS abusers, increased voluntary alcohol consumption
after cessation of AAS administration has also been observed
in male adult rats (Johansson et al., 2000b). In line with
these findings, corticotropin releasing factor modulation of
GABAergic transmission in the amygdala seems to play a
pivotal role in ethanol effects, suggesting that AAS might
alter the sensitivity of these circuits and predispose to alcohol
abuse (Roberto et al., 2004, 2010; Oberlander and Henderson,
2012). Chronic nandrolone decanoate administration has
been found to significantly impair CPP induced by 19-
tetrahydrocannabinol (THC) without affecting CB1 receptor
binding. Interestingly, nandrolone administration increased
THC abstinence precipitated by the CB1 cannabinoid antagonist
rimonabant (Celerier et al., 2006).
Administration of supra-pharmacological doses of
nandrolone decanoate has been shown to decrease the hyper-
locomotion and stereotyped behavior induced by amphetamine
and MDMA, in a dose-dependent manner (Kurling et al.,
2008). Such behavioral outcomes have been corroborated by
microdialysis results. In particular, nandrolone decanoate
attenuated the effect of amphetamine and MDMA on DA
baseline and DA metabolites levels in the NAc. However,
the higher dose of nandrolone decanoate has enhanced the
acute effects of MDMA-induced release of 5-HT, followed by
exhaustion of neuronal 5-HT stores. Thus, high-dose nandrolone
decanoate treatment might enhance neuron vulnerability to
MDMA, leading to effects resembling MDMA neurotoxicity
(Kurling et al., 2008). In addition, it has been demonstrated
that the effects of amphetamine on the hippocampal and
hypothalamic DOPAC/DA ratio were prevented by nandrolone
decanoate, with no changes to DA baseline levels (Birgner
et al., 2007). Likewise, it has been shown that pretreatment
with nandrolone decanoate attenuates accumbal DA and 5-HT
outflow, as well as the consequent stereotyped behavior induced
by cocaine (Kurling-Kailanto et al., 2010; Kailanto et al., 2011).
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Nandrolone might decrease neurochemical and behavioral
effects induced by cocaine via up-regulation of DAT and SERT
binding sites. In these studies, the authors showed that changes
in DA and 5-HT systems endure, even after a long recovery
period from the last dose of nandrolone. This confirms the
hypothesis that drug abuse causes long lasting changes in brain
dopaminergic and serotonergic pathways (Kurling et al., 2008;
Kailanto et al., 2011). These data are in line with earlier findings
demonstrating that chronic cocaine and methamphetamine
decreased D2-receptor and DAT expression during withdrawal
and lasted up to 11 months after the last drug administration
(Volkow et al., 1990, 2001a,b). Collectively, these results
demonstrate that pre-treatment with nandrolone decanoate
dose-dependently attenuates neurochemical and behavioral
effects relating to the reward system induced by psychostimulant
drugs. These findings indicate that such reduced dopaminergic
and serotonergic activity in brain regions strictly involved in
the reward system might represent the neurochemical substrate
that could underlie a higher prevalence of illicit drug use
among AAS abusers. Indeed, to achieve the desired effect of
psychostimulant drugs, AAS users may require increased doses
of these substances.
On the other hand, testosterone has been hypothesized
to act as a partial agonist on the opiod system considering
that, depending on type of receptors involved, steroid effects
are brain region specific (Wood, 2008). As the reinforcing
effects of opioids are thought to be mediated principally by
µ- and δ-receptors (Peters and Wood, 2005), many data
in the literature are available with regard to altered opioid
receptor binding after AAS. In particular, nandrolone has
been reported to increase binding of µ-, δ-, and κ-receptors
in the hypothalamus, striatum, and midbrain periaqueductal
gray (Johansson et al., 2000a), while reduced κ-receptors have
been found in NAc (Johansson et al., 2000b). In addition,
increased β-endorphin levels in the VTA (Johansson et al.,
1997) and paraventricular thalamus (PVT) (Harlan et al.,
2000) along with and higher β-endorphin fiber staining in
bed nucleus of the stria terminalis and PVT (Menard et al.,
1995) have been described. However, the total β-endorphin
immunoreactivity is lower in arcuate nucleus (Menard et al.,
1995).
On the other hand, nandrolone has been found to enhance
morphine-induced hypothermia while testosterone increases the
antinociceptive effect of a κ-agonist. However, contrasting data
exist since no effects of AAS on morphine antinociception have
been reported in other animal models (Negus et al., 2001; Celerier
et al., 2003; Philipova et al., 2003). In fact, nandrolone pre-
exposure has been shown to inhibit tolerance to antinociceptive
properties of morphine and CPP induced by morphine in
mice (Celerier et al., 2003) and rats (Philipova et al., 2003).
Accordingly, pre-exposure to AAS has been shown to prevent
morphine-induced striatal Fos expression (Harlan et al., 2000).
High variability is present in findings linking AAS to opiate
withdrawal. In monkeys no effect of AAS has been described for
naloxone-precipitated morphine withdrawal paradigm, although
Celerier et al. (2003) found that nandrolone increased withdrawal
symptoms induced by naloxone in morphine-dependent mice.
Moreover, the dysphoric effect mediated by nandrolone pre-
treatment has been correlated to elevated striatal levels of
dynorphin B, which in turn may account for the inhibition of
dopaminergic activity in this brain region (Steiner and Gerfen,
1998; Johansson et al., 2000a). Finally, testosterone has been
shown not to increase motivation for morphine (Cooper and
Wood, 2014). Such discrepancies may rely on different AAS and
schedule of treatment used, as well as different species or strain
of animal used.
Although literature has been populated by many clinical or
preclinical reports, many knots in the unraveling of deleterious
addictive effects of AAS still need to be untied. Furthermore,
taking into account that the use of these substances is becoming
popular, especially among adolescents, a deeper knowledge of
CNS effects of AAS is nowadays mandatory.
Funding
This review was supported by PRIN 2011 (PT) fromMIUR.
References
Aitken, C., Delalande, C., and Stanton, K. (2002). Pumping iron, risking infection?
Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic
steroid injectors in Victoria, Australia. Drug Alcohol Depend. 65, 303–308. doi:
10.1016/S0376-8716(01)00174-0
Alexander, G. M., Packard, M. G., and Hines, M. (1994). Testosterone has
rewarding affective properties in male rats: implications for the biological
basis of sexual motivation. Behav. Neurosci. 108, 424–428. doi: 10.1037/0735-
7044.108.2.424
Ambar, G., and Chiavegatto, S. (2009). Anabolic-androgenic steroid treatment
induces behavioral disinhibition and downregulation of serotonin
receptor messenger RNA in the prefrontal cortex and amygdala of male
mice. Genes Brain Behav. 8, 161–173. doi: 10.1111/j.1601-183X.2008.
00458.x
Anderson, R. A., and Wu, F. C. (1996). Comparison between testosterone
enanthate-induced azoospermia and oligozoospermia in a male contraceptive
study. II. Pharmacokinetics and pharmacodynamics of once weekly
administration of testosterone enanthate. J. Clin. Endocrinol. Metab. 81,
896–901.
Arnedo, M. T., Salvador, A., Martinez-Sanchis, S., and Gonzalez-Bono, E. (2000).
Rewarding properties of testosterone in intact male mice: a pilot study.
Pharmacol. Biochem. Behav. 65, 327–332. doi: 10.1016/S0091-3057(99)00189-6
Arnedo, M. T., Salvador, A., Martínez-Sanchís, S., and Pellicer, O. (2002). Similar
rewarding effects of testosterone in mice rated as short and long attack latency
individuals. Addict. Biol. 7, 373–379. doi: 10.1080/1355621021000005955
Arvary, D., and Pope, H. G. Jr. (2000). Anabolic-androgenic steroids as
a gateway to opioid dependence. N. Engl. J. Med. 342, 1532. doi:
10.1056/NEJM200005183422018
Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Picard, M. H.,
Hutter, A. M. Jr., et al. (2010). Long-term anabolic-androgenic steroid use is
associated with left ventricular dysfunction. Circ. Heart Fail. 3, 472–476. doi:
10.1161/CIRCHEARTFAILURE.109.931063
Bahrke, M. S., and Yesalis, C. E. III. (1994). Weight training. A potential
confounding factor in examining the psychological and behavioural effects of
anabolic-androgenic steroids. Sports Med. 18, 309–318. doi: 10.2165/00007256-
199418050-00003
Ballard, C. L., and Wood, R. I. (2005). Intracerebroventricular self-administration
of commonly abused anabolic-androgenic steroids in male hamsters
(Mesocricetus auratus): nandrolone, drostanolone, oxymetholone, and
Frontiers in Neuroscience | www.frontiersin.org 9 August 2015 | Volume 9 | Article 295
Mhillaj et al. Anabolic-androgens and brain reward
stanozolol. Behav. Neurosci. 119, 752–758. doi: 10.1037/0735-7044.119.
3.752
Basaria, S., Wahlstrom, J. T., and Dobs, A. S. (2001). Clinical review 138: anabolic-
androgenic steroid therapy in the treatment of chronic diseases. J. Clin.
Endocrinol. Metab. 86, 5108–5117. doi: 10.1210/jcem.86.11.7983
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips,
J., et al. (1996). The effects of supraphysiologic doses of testosterone on
muscle size and strength in normal men. N. Engl. J. Med. 335, 1–7. doi:
10.1056/NEJM199607043350101
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., et al.
(2001). Testosterone dose-response relationships in healthy young men. Am. J.
Physiol. Endocrinol. Metab. 281, E1172–E1181.
Birgner, C., Kindlundh-Hogberg, A. M., Alsio, J., Lindblom, J., Schioth, H. B., and
Bergstrom, L. (2008a). The anabolic androgenic steroid nandrolone decanoate
affects mRNA expression of dopaminergic but not serotonergic receptors. Brain
Res. 1240, 221–228. doi: 10.1016/j.brainres.2008.09.003
Birgner, C., Kindlundh-Högberg, A. M., Nyberg, F., and Bergström, L. (2007).
Altered extracellular levels of DOPAC and HVA in the rat nucleus
accumbens shell in response to sub-chronic nandrolone administration and
a subsequent amphetamine challenge. Neurosci. Lett. 412, 168–172. doi:
10.1016/j.neulet.2006.11.001
Birgner, C., Kindlundh-Högberg, A. M., Oreland, L., Alsiö, J., Lindblom, J.,
Schiöth, H. B., et al. (2008b). Reduced activity of monoamine oxidase in the
rat brain following repeated nandrolone decanoate administration. Brain Res.
1219, 103–110. doi: 10.1016/j.brainres.2008.05.014
Bonson, K. R., Johnson, R. G., Fiorella, D., Rabin, R. A., and Winter, J. C. (1994).
Serotonergic control of androgen-induced dominance. Pharmacol. Biochem.
Behav. 49, 313–322. doi: 10.1016/0091-3057(94)90427-8
Breuer, M. E., McGinnis, M. Y., Lumia, A. R., and Possidente, B. P. (2001).
Aggression in male rats receiving anabolic androgenic steroids: effects of
social and environmental provocation. Horm. Behav. 40, 409–418. doi:
10.1006/hbeh.2001.1706
Brower, K. J. (1997). Withdrawal from anabolic steroids. Curr. Ther. Endocrinol.
Metab. 6, 338–343.
Brower, K. J. (2000). “Anabolic steroids: potential for physical and psychological
dependence,” in Anabolic Steroids in Sport and Exercise, 2nd Edn.,
ed C. E. Yesalis (Champaign, IL: Human Kinetics), 280–304.
Brower, K. J. (2002). Anabolic steroid abuse and dependence. Curr. Psychiatry Rep.
4, 377–387. doi: 10.1007/s11920-002-0086-6
Brower, K. J., Blow, F. C., Young, J. P., and Hill, E. M. (1991). Symptoms
and correlates of anabolic-androgenic steroid dependence. Br. J. Addict. 86,
759–768. doi: 10.1111/j.1360-0443.1991.tb03101.x
Brower, K. J., Eliopulos, G. A., Blow, F. C., Catlin, D. H., and Beresford, T.
P. (1990). Evidence for physical and psychological dependence on anabolic
androgenic steroids in eight weight lifters. Am. J. Psychiatry 147, 510–512. doi:
10.1176/ajp.147.4.510
Célérier, E., Ahdepil, T., Wikander, H., Berrendero, F., Nyberg, F., and
Maldonado, R. (2006). Influence of the anabolic-androgenic steroid
nandrolone on cannabinoid dependence. Neuropharmacology 50, 788–806.
doi: 10.1016/j.neuropharm.2005.11.017
Célérier, E., Yazdi, M. T., Castañé, A., Ghozland, S., Nyberg, F., and Maldonado,
R. (2003). Effects of nandrolone on acute morphine responses, tolerance
and dependence in mice. Eur. J. Pharmacol. 465, 69–81. doi: 10.1016/S0014-
2999(03)01462-6
Christie, M. H., and Barfield, R. J. (1979). Effects of aromatizable androgens on
aggressive behaviour among rats (rattus norvegicus). J. Endocrinol. 83, 17–26.
doi: 10.1677/joe.0.0830017
Clark, A. S., and Barber, D. M. (1994). Anabolic-androgenic steroids and
aggression in castrated male rats. Physiol. Behav. 56, 1107–1113. doi:
10.1016/0031-9384(94)90351-4
Clark, A. S., and Henderson, L. P. (2003). Behavioral and physiological responses
to anabolic-androgenic steroids. Neurosci. Biobehav. Rev. 27, 413–436. doi:
10.1016/S0149-7634(03)00064-2
Clark, A. S., Lindenfeld, R. C., and Gibbons, C. H. (1996). Anabolic-androgenic
steroids and brain reward. Pharmacol. Biochem. Behav. 53, 741–745. doi:
10.1016/0091-3057(95)02082-9
Conway, A. J., Handelsman, D. J., Lording, D. W., Stuckey, B., and Zajac, J.
D. (2000). Use, misuse and abuse of androgens. The Endocrine Society of
Australia consensus guidelines for androgen prescribing. Med. J. Aust. 172,
220–224.
Cooper, S. E., and Wood, R. I. (2014). Androgens and opiates: testosterone
interaction with morphine self-administration in male rats. Neuroreport 25,
521–526. doi: 10.1097/wnr.0000000000000125
Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., and
Bhasin, S. (2008). Effects of graded doses of testosterone on erythropoiesis in
healthy young and older men. J. Clin. Endocrinol. Metab. 93, 914–919. doi:
10.1210/jc.2007-1692
Cunningham, R. L., and McGinnis, M. Y. (2006). Physical provocation of pubertal
anabolic androgenic steroid exposed male rats elicits aggression towards
females. Horm. Behav. 50, 410–416. doi: 10.1016/j.yhbeh.2006.05.002
Cunningham, R. L., and McGinnis, M. Y. (2007). Factors influencing aggression
toward females by male rats exposed to anabolic androgenic steroids during
puberty. Horm. Behav. 51, 135–141. doi: 10.1016/j.yhbeh.2006.09.003
Daly, R. C., Su, T. P., Schmidt, P. J., Pickar, D., Murphy, D. L., and Rubinow, D.
R. (2001). Cerebrospinal fluid and behavioral changes after methyltestosterone
administration: preliminary findings. Arch. Gen. Psychiatry 58, 172–177. doi:
10.1001/archpsyc.58.2.172
Dean, C. E. (2000). Prasterone (DHEA) and mania. Ann. Pharmacother. 34,
1419–1422. doi: 10.1345/aph.10115
de Beun, R., Jansen, E., Slangen, J. L., and Van de Poll, N. E. (1992). Testosterone as
appetitive and discriminative stimulus in rats: sex- and dose-dependent effects.
Physiol. Behav. 52, 629–634. doi: 10.1016/0031-9384(92)90389-J
de Souza Silva, M. A., Mattern, C., Topic, B., Buddenberg, T. E., and Huston,
J. P. (2009). Dopaminergic and serotonergic activity in neostriatum and
nucleus accumbens enhanced by intranasal administration of testosterone. Eur.
Neuropsychopharmacol. 19, 53–63. doi: 10.1016/j.euroneuro.2008.08.003
DiMeo, A. N., andWood, R. I. (2004). Circulating androgens enhance sensitivity to
testosterone self-administration in male hamsters. Pharmacol. Biochem. Behav.
79, 383–389. doi: 10.1016/j.pbb.2004.08.015
Dohle, G. R., Smit, M., and Weber, R. F. (2003). Androgens and male fertility.
World J. Urol. 21, 341–345. doi: 10.1007/s00345-003-0365-9
DuRant, R. H., Escobedo, L. G., and Heath, G. W. (1995). Anabolic-steroid use,
strength training, and multiple drug use among adolescents in the United
States. Pediatrics 96, 23–28.
Ernst, M., Romeo, R. D., and Andersen, S. L. (2009). Neurobiology of
the development of motivated behaviors in adolescence: a window into
a neural systems model. Pharmacol. Biochem. Behav. 93, 199–211. doi:
10.1016/j.pbb.2008.12.013
Far, H. R., Ågren, G., and Thiblin, I. (2012). Cardiac hypertrophy in deceased
users of anabolic androgenic steroids: an investigation of autopsy findings.
Cardiovasc. Pathol. 21, 312–316. doi: 10.1016/j.carpath.2011.10.002
Farrell, S. F., and McGinnis, M. Y. (2003). Effects of pubertal anabolic-androgenic
steroid (AAS) administration on reproductive and aggressive behaviors in male
rats. Behav. Neurosci. 117, 904–911. doi: 10.1037/0735-7044.117.5.904
Ferreira, I., Brooks, D., Lacasse, Y., and Goldstein, R. (2001). Nutritional
intervention in COPD: a systematic overview. Chest 119, 353–363. doi:
10.1378/chest.119.2.353
Foradori, C. D., Weiser, M. J., and Handa, R. J. (2008). Non-genomic
actions of androgens. Front. Neuroendocrinol. 29, 169–181. doi:
10.1016/j.yfrne.2007.10.005
Franke, W. W., and Berendonk, B. (1997). Hormonal doping and androgenization
of athletes: a secret program of the German Democratic Republic government.
Clin. Chem. 43, 1262–1279.
Frye, C. A. (2007). Some rewarding effects of androgens may be mediated by
actions of its 5alpha-reduced metabolite 3alpha-androstanediol. Pharmacol.
Biochem. Behav. 86, 354–367. doi: 10.1016/j.pbb.2006.10.003
Frye, C. A., Babson, A., and Walf, A. A. (2007). Self-administration of 3alpha-
androstanediol increases locomotion and analgesia and decreases aggressive
behavior of male hamsters. Pharmacol. Biochem. Behav. 86, 415–421. doi:
10.1016/j.pbb.2006.05.025
Frye, C. A., Park, D., Tanaka, M., Rosellini, R., and Svare, B. (2001).
The testosterone metabolite and neurosteroid 3alpha-androstanediol may
mediate the effects of testosterone on conditioned place preference.
Psychoneuroendocrinology 26, 731–750. doi: 10.1016/S0306-4530(01)00027-0
Frye, C. A., Rhodes, M. E., Rosellini, R., and Svare, B. (2002). The nucleus
accumbens as a site of action for rewarding properties of testosterone and
Frontiers in Neuroscience | www.frontiersin.org 10 August 2015 | Volume 9 | Article 295
Mhillaj et al. Anabolic-androgens and brain reward
its 5alpha-reduced metabolites. Pharmacol. Biochem. Behav. 74, 119–127. doi:
10.1016/S0091-3057(02)00968-1
Furlanello, F., Bentivegna, S., Cappato, R., and De Ambroggi, L. (2003).
Arrhythmogenic effects of illicit drugs in athletes. Ital. Heart J. 4, 829–837.
Galvan, A. (2010). Adolescent development of the reward system. Front. Hum.
Neurosci. 4:6. doi: 10.3389/neuro.09.006.2010
Gianoulakis, C. (2009). Endogenous opioids and addiction to alcohol
and other drugs of abuse. Curr. Top. Med. Chem. 9, 999–1015. doi:
10.2174/156802609789630956
Grimes, J. M., and Melloni, R. H. Jr. (2005). Serotonin-1B receptor activity
and expression modulate the aggression-stimulating effects of adolescent
anabolic steroid exposure in hamsters. Behav. Neurosci. 119, 1184–1194. doi:
10.1037/0735-7044.119.5.1184
Gupta, V., Bhasin, S., Guo, W., Singh, R., Miki, R., Chauhan, P., et al. (2008).
Effects of dihydrotestosterone on differentiation and proliferation of human
mesenchymal stem cells and preadipocytes. Mol. Cell. Endocrinol. 296, 32–40.
doi: 10.1016/j.mce.2008.08.019
Hallberg, M., Johansson, P., Kindlundh, A. M., and Nyberg, F. (2000). Anabolic-
androgenic steroids affect the content of substance P and substance P(1-7) in
the rat brain. Peptides 21, 845–852. doi: 10.1016/S0196-9781(00)00218-7
Harlan, R. E., Brown, H. E., Lynch, C. S., D’Souza, D., and Garcia, M. M. (2000).
Androgenic-anabolic steroids blunt morphine-induced c-fos expression in the
rat striatum: possible role of beta-endorphin. Brain Res. 853, 99–104. doi:
10.1016/S0006-8993(99)02257-X
Harrison, R. J., Connor, D. F., Nowak, C., Nash, K., and Melloni, R. H. Jr.
(2000). Chronic anabolic-androgenic steroid treatment during adolescence
increases anterior hypothalamic vasopressin and aggression in intact hamsters.
Psychoneuroendocrinology 25, 317–338. doi: 10.1016/S0306-4530(99)00057-8
Hart, D. W., Wolf, S. E., Ramzy, P. I., Chinkes, D. L., Beauford, R. B., Ferrando, A.
A., et al. (2001). Anabolic effects of oxandrolone after severe burn. Ann. Surg.
233, 556–564. doi: 10.1097/00000658-200104000-00012
Hassan, N. A., Salem, M. F., and Sayed, M. A. (2009). Doping and effects of
anabolic androgenic steroids on the heart: histological, ultrastructural, and
echocardiographic assessment in strength athletes. Hum. Exp. Toxicol. 28,
273–283. doi: 10.1177/0960327109104821
Haupt, H. A. (2001). Upper extremity injuries associated with strength training.
Clin. Sports Med. 20, 481–490. doi: 10.1016/S0278-5919(05)70264-7
Irving, L. M., Wall, M., Neumark-Sztainer, D., and Story, M. (2002). Steroid use
among adolescents: findings from Project EAT. J. Adolesc. Health 30, 243–252.
doi: 10.1016/S1054-139X(01)00414-1
Johansson, P., Hallberg, M., Kindlundh, A., and Nyberg, F. (2000a). The effect
on opioid peptides in the rat brain, after chronic treatment with the anabolic
androgenic steroid, nandrolone decanoate. Brain Res. Bull. 51, 413–418. doi:
10.1016/S0361-9230(99)00263-4
Johansson, P., Lindqvist, A., Nyberg, F., and Fahlke, C. (2000b). Anabolic
androgenic steroids affects alcohol intake, defensive behaviors and brain
opioid peptides in the rat. Pharmacol. Biochem. Behav. 67, 271–279. doi:
10.1016/S0091-3057(00)00365-8
Johansson, P., Ray, A., Zhou, Q., Huang, W., Karlsson, K., and Nyberg, F.
(1997). Anabolic androgenic steroids increase beta-endorphin levels in the
ventral tegmental area in the male rat brain. Neurosci. Res. 27, 185–189. doi:
10.1016/S0168-0102(96)01141-8
Johnson, L. R., and Wood, R. I. (2001). Oral testosterone self-administration in
male hamsters. Neuroendocrinology 73, 285–292. doi: 10.1159/000054645
Kailanto, S., Kankaanpää, A., and Seppälä, T. (2011). Subchronic steroid
administration induces long lasting changes in neurochemical and
behavioral response to cocaine in rats. Steroids 76, 1310–1316. doi:
10.1016/j.steroids.2011.06.011
Kanayama, G., Cohane, G. H., Weiss, R. D., and Pope, H. G. (2003a). Past
anabolic-androgenic steroid use among men admitted for substance abuse
treatment: an underrecognized problem? J. Clin. Psychiatry 64, 156–160. doi:
10.4088/JCP.v64n0208
Kanayama, G., Hudson, J. I., and Pope, H. G. Jr. (2009). Features of men with
anabolic-androgenic steroid dependence: a comparison with nondependent
AAS users and with AAS nonusers. Drug Alcohol Depend. 102, 130–137. doi:
10.1016/j.drugalcdep.2009.02.008
Kanayama, G., Pope, H. G., Cohane, G., and Hudson, J. I. (2003b). Risk factors
for anabolic-androgenic steroid use among weightlifters: a case-control study.
Drug Alcohol Depend. 71, 77–86. doi: 10.1016/S0376-8716(03)00069-3
Kashkin, K. B., and Kleber, H. D. (1989). Hooked on hormones? An
anabolic steroid addiction hypothesis. JAMA 262, 3166–3170. doi:
10.1001/jama.1989.03430220089036
Kindlundh, A. M., Bergström, M., Monazzam, A., Hallberg, M., Blomqvist, G.,
Långström, B., et al. (2002). Dopaminergic effects after chronic treatment with
nandrolone visualized in rat brain by positron emission tomography. Prog.
Neuropsychopharmacol. Biol. Psychiatry 26, 1303–1308. doi: 10.1016/S0278-
5846(02)00293-2
Kindlundh, A. M., Hagekull, B., Isacson, D. G., and Nyberg, F. (2001a). Adolescent
use of anabolic-androgenic steroids and relations to self-reports of social,
personality and health aspects. Eur. J. Public Health 11, 322–328. doi:
10.1093/eurpub/11.3.322
Kindlundh, A. M., Isacson, D. G., Berglund, L., and Nyberg, F. (1999). Factors
associated with adolescent use of doping agents: anabolic-androgenic steroids.
Addiction 94, 543–553. doi: 10.1046/j.1360-0443.1999.9445439.x
Kindlundh, A. M., Lindblom, J., Bergström, L., Wikberg, J. E., and Nyberg, F.
(2001b). The anabolic-androgenic steroid nandrolone decanoate affects the
density of dopamine receptors in the male rat brain. Eur. J. Neurosci. 13,
291–296. doi: 10.1046/j.0953-816X.2000.01402.x
Kindlundh, A. M., Lindblom, J., and Nyberg, F. (2003). Chronic administration
with nandrolone decanoate induces alterations in the gene-transcript content
of dopamine D(1)- and D(2)-receptors in the rat brain. Brain Res. 979, 37–42.
doi: 10.1016/S0006-8993(03)02843-9
Koob, G. F. (2006). The neurobiology of addiction: a neuroadaptational view
relevant for diagnosis. Addiction 101(Suppl. 1), 23–30. doi: 10.1111/j.1360-
0443.2006.01586.x
Krieg, A., Scharhag, J., Albers, T., Kindermann, W., and Urhausen, A. (2007).
Cardiac tissue Doppler in steroid users. Int. J. Sports Med. 28, 638–643. doi:
10.1055/s-2007-964848
Kritzer, M. F., and Creutz, L. M. (2008). Region and sex differences in
constituent dopamine neurons and immunoreactivity for intracellular estrogen
and androgen receptors in mesocortical projections in rats. J. Neurosci. 28,
9525–9535. doi: 10.1523/JNEUROSCI.2637-08.2008
Kuhn, C. M. (2002). Anabolic steroids. Recent Prog. Horm. Res. 57, 411–434. doi:
10.1210/rp.57.1.411
Kurling, S., Kankaanpää, A., and Seppälä, T. (2008). Sub-chronic nandrolone
treatment modifies neurochemical and behavioral effects of amphetamine and
3,4-methylenedioxymethamphetamine (MDMA) in rats. Behav. Brain Res. 189,
191–201. doi: 10.1016/j.bbr.2007.12.021
Kurling-Kailanto, S., Kankaanpää, A., and Seppälä, T. (2010). Subchronic
nandrolone administration reduces cocaine-induced dopamine and 5-
hydroxytryptamine outflow in the rat nucleus accumbens. Psychopharmacology
(Berl.) 209, 271–281. doi: 10.1007/s00213-010-1796-9
Kutscher, E. C., Lund, B. C., and Perry, P. J. (2002). Anabolic steroids: a review
for the clinician. Sports Med. 32, 285–296. doi: 10.2165/00007256-200232050-
00001
Langer, C. J., Hoffman, J. P., and Ottery, F. D. (2001). Clinical significance of
weight loss in cancer patients: rationale for the use of anabolic agents in the
treatment of cancer-related cachexia. Nutrition 17, S1–S20. doi: 10.1016/s0899-
9007(01)80001-0
Le Grevès, P., Huang, W., Johansson, P., Thörnwall, M., Zhou, Q., and Nyberg,
F. (1997). Effects of an anabolic-androgenic steroid on the regulation of the
NMDA receptor NR1, NR2A and NR2B subunit mRNAs in brain regions of
the male rat. Neurosci. Lett. 226, 61–64. doi: 10.1016/S0304-3940(97)00244-9
Li, S., Kang, L., Zhang, Y., Feng, B., Du, J., and Cui, H. (2015). Detecting the
presence of hippocampus membrane androgen receptors in male SAMP8 mice
and their induced synaptic plasticity. Mol. Cell. Endocrinol. 414, 82–90. doi:
10.1016/j.mce.2015.07.005
Lindqvist, A. S., Johansson-Steensland, P., Nyberg, F., and Fahlke, C. (2002).
Anabolic androgenic steroid affects competitive behaviour, behavioural
response to ethanol and brain serotonin levels. Behav. Brain Res. 133, 21–29.
doi: 10.1016/S0166-4328(01)00408-9
Long, S. F., Wilson, M. C., and Davis, W. M. (2000). The effects of nandrolone
decanoate on cocaine-induced kindling in male rats. Neuropharmacology 39,
2442–2447. doi: 10.1016/S0028-3908(00)00061-7
Long, S. F., Wilson, M. C., Sufka, K. J., and Davis, W. M. (1996). The effects
of cocaine and nandrolone co-administration on aggression in male rats.
Prog. Neuropsychopharmacol. Biol. Psychiatry 20, 839–856. doi: 10.1016/0278-
5846(96)00063-2
Frontiers in Neuroscience | www.frontiersin.org 11 August 2015 | Volume 9 | Article 295
Mhillaj et al. Anabolic-androgens and brain reward
Luijkx, T., Velthuis, B. K., Backx, F. J., Buckens, C. F., Prakken, N. H., Rienks,
R., et al. (2013). Anabolic androgenic steroid use is associated with ventricular
dysfunction on cardiac MRI in strength trained athletes. Int. J. Cardiol. 167,
664–668. doi: 10.1016/j.ijcard.2012.03.072
Lumia, A. R., and McGinnis, M. Y. (2010). Impact of anabolic androgenic
steroids on adolescent males. Physiol. Behav. 100, 199–204. doi:
10.1016/j.physbeh.2010.01.007
Lumia, A. R., Thorner, K. M., and McGinnis, M. Y. (1994). Effects of chronically
high doses of the anabolic androgenic steroid, testosterone, on intermale
aggression and sexual behavior in male rats. Physiol. Behav. 55, 331–335. doi:
10.1016/0031-9384(94)90142-2
Magnusson, K., Birgner, C., Bergström, L., Nyberg, F., and Hallberg, M. (2009).
Nandrolone decanoate administration dose-dependently affects the density of
kappa opioid peptide receptors in the rat brain determined by autoradiography.
Neuropeptides 43, 105–111. doi: 10.1016/j.npep.2008.12.005
Magnusson, K., Hallberg, M., Bergquist, J., and Nyberg, F. (2007).
Enzymatic conversion of dynorphin A in the rat brain is affected by
administration of nandrolone decanoate. Peptides 28, 851–858. doi:
10.1016/j.peptides.2006.12.011
Manoharan, G., Campbell, N. P., and O’Brien, C. J. (2002). Syncopal episodes
in a young amateur body builder. Br. J. Sports Med. 36, 67–68. doi:
10.1136/bjsm.36.1.67
Martinez-Rivera, F. J., Natal-Albelo, E. J., Martínez, N. A., Orozco-Vega, R.
A., Muñiz-Seda, O. A., and Barreto-Estrada, J. L. (2015). The effect of
the anabolic steroid, nandrolone, in conditioned place preference and D1
dopamine receptor expression in adolescent and adult mice. Behav. Processes
113, 81–85. doi: 10.1016/j.beproc.2015.01.008
Martínez-Sanchis, S., Brain, P. F., Salvador, A., and Simón, V. M. (1996). Long-
term chronic treatment with stanozolol lacks significant effects on aggression
and activity in young and adult male laboratory mice. Gen. Pharmacol. 27,
293–298. doi: 10.1016/0306-3623(95)02019-5
McBride, A. J., Williamson, K., and Petersen, T. (1996). Three cases of nalbuphine
hydrochloride dependence associated with anabolic steroid use. Br. J. Sports
Med. 30, 69–70. doi: 10.1136/bjsm.30.1.69
McGinnis, M. Y. (2004). Anabolic androgenic steroids and aggression:
studies using animal models. Ann. N.Y. Acad. Sci. 1036, 399–415. doi:
10.1196/annals.1330.024
McGinnis, M. Y., Lumia, A. R., Breuer, M. E., and Possidente, B. (2002a). Physical
provocation potentiates aggression in male rats receiving anabolic androgenic
steroids. Horm. Behav. 41, 101–110. doi: 10.1006/hbeh.2001.1742
McGinnis, M. Y., Lumia, A. R., and Possidente, B. P. (2002b). Effects of withdrawal
from anabolic androgenic steroids on aggression in adult male rats. Physiol.
Behav. 75, 541–549. doi: 10.1016/S0031-9384(02)00657-1
McQueen, J. K., Wilson, H., Sumner, B. E., and Fink, G. (1999). Serotonin
transporter (SERT) mRNA and binding site densities in male rat brain affected
by sex steroids. Brain Res. Mol. Brain Res. 63, 241–247. doi: 10.1016/S0169-
328X(98)00281-2
Menard, C. S., Hebert, T. J., Dohanich, G. P., andHarlan, R. E. (1995). Androgenic-
anabolic steroids modify beta-endorphin immunoreactivity in the rat brain.
Brain Res. 669, 255–262. doi: 10.1016/0006-8993(94)01266-K
Midgley, S. J., Heather, N., and Davies, J. B. (1999). Dependence-producing
potential of anabolic-androgenic steroids. Addict. Res. Theory 7, 539–550. doi:
10.3109/16066359909004404
Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998).
Dopamine receptors: from structure to function. Physiol. Rev. 78, 189–225.
Montisci, M., El Mazloum, R., Cecchetto, G., Terranova, C., Ferrara, S. D., Thiene,
G., et al. (2012). Anabolic androgenic steroids abuse and cardiac death in
athletes: morphological and toxicological findings in four fatal cases. Forensic
Sci. Int. 217, e13–e18. doi: 10.1016/j.forsciint.2011.10.032
Morley, J. E. (2001). Testosterone replacement in older men and women. J. Gend.
Specif. Med. 4, 49–53.
Morton, R., Gleason, O., and Yates, W. (2000). Psychiatric effects of anabolic
steroids after burn injuries. Psychosomatics 41, 66–68. doi: 10.1016/S0033-
3182(00)71176-5
Negus, S. S., Pope, H. G. Jr., Kanayama, G., Wines, J. D. Jr., and Fischer, B.
D. (2001). Lack of evidence for opioid tolerance or dependence in rhesus
monkeys following high-dose anabolic-androgenic steroid administration.
Psychoneuroendocrinology 26, 789–796. doi: 10.1016/S0306-4530(01)00028-2
Noakes, T. D. (2004). Tainted glory–doping and athletic performance. N. Engl. J.
Med. 351, 847–849. doi: 10.1056/NEJMp048208
Oberlander, J. G., and Henderson, L. P. (2012). Corticotropin-releasing
factor modulation of forebrain GABAergic transmission has a pivotal
role in the expression of anabolic steroid-induced anxiety in the female
mouse. Neuropsychopharmacology 37, 1483–1499. doi: 10.1038/npp.
2011.334
Packard, M. G., Cornell, A. H., and Alexander, G. M. (1997). Rewarding
affective properties of intra-nucleus accumbens injections of testosterone.
Behav. Neurosci. 111, 219–224. doi: 10.1037/0735-7044.111.1.219
Parkinson, A. B., and Evans, N. A. (2006). Anabolic androgenic steroids:
a survey of 500 users. Med. Sci. Sports Exerc. 38, 644–651. doi:
10.1249/01.mss.0000210194.56834.5d
Parrilla-Carrero, J., Figueroa, O., Lugo, A., Garcia-Sosa, R., Brito-Vargas,
P., Cruz, B., et al. (2009). The anabolic steroids testosterone propionate
and nandrolone, but not 17alpha-methyltestosterone, induce conditioned
place preference in adult mice. Drug Alcohol Depend. 100, 122–127. doi:
10.1016/j.drugalcdep.2008.09.014
Pärssinen, M., and Seppälä, T. (2002). Steroid use and long-term health risks
in former athletes. Sports Med. 32, 83–94. doi: 10.2165/00007256-200232020-
00001
Peters, K. D., andWood, R. I. (2005). Androgen dependence in hamsters: overdose,
tolerance, and potential opioidergic mechanisms. Neuroscience 130, 971–981.
doi: 10.1016/j.neuroscience.2004.09.063
Philipova, T., Ivanova, T., Pavlova, E., Kasakov, L., and Vlaskovska, M.
(2003). Nandrolone modulates the non-opioid and opioid analgesia and
tolerance/dependence: role of sexual dimorphism. Arch. Physiol. Biochem. 111,
429–436. doi: 10.3109/13813450312331342283
Polsky, B., Kotler, D., and Steinhart, C. (2001). HIV-associated wasting in the
HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient
Care STDS 15, 411–423. doi: 10.1089/108729101316914412
Pope, H. G. J., and Brower, K. J. (2000). “Anabolic-androgenic steroid
abuse,” in Comprehensive Textbook of Psychiatry, eds B. J. Sadock, V. A.
Sadock, and P. Ruiz, (Philadelphia, PA: Lippincott Williams & Wilkins),
1085–1095.
Pope, H. G. Jr., Kouri, E. M., and Hudson, J. I. (2000). Effects of supraphysiologic
doses of testosterone on mood and aggression in normal men: a randomized
controlled trial. Arch. Gen. Psychiatry 57, 133–140. discussion 155–136. doi:
10.1001/archpsyc.57.2.133
Pope, H. G. Jr., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., and Bhasin, S. (2014).
Adverse health consequences of performance-enhancing drugs: an Endocrine
Society scientific statement. Endocr. Rev. 35, 341–375. doi: 10.1210/er.2013-
1058
Porcerelli, J. H., and Sandler, B. A. (1995). Narcissism and empathy in steroid users.
Am. J. Psychiatry 152, 1672–1674. doi: 10.1176/ajp.152.11.1672
Rabkin, J. G., Wagner, G. J., and Rabkin, R. (2000). A double-blind, placebo-
controlled trial of testosterone therapy for HIV-positive men with hypogonadal
symptoms. Arch. Gen. Psychiatry 57, 141–147. discussion 155–146. doi:
10.1001/archpsyc.57.2.141
Ricci, L. A., Grimes, J. M., and Melloni, R. H. Jr. (2007). Lasting changes in
neuronal activation patterns in select forebrain regions of aggressive, adolescent
anabolic/androgenic steroid-treated hamsters. Behav. Brain Res. 176, 344–352.
doi: 10.1016/j.bbr.2006.10.025
Ricci, L. A., Rasakham, K., Grimes, J. M., and Melloni, R. H. Jr. (2006). Serotonin-
1A receptor activity and expression modulate adolescent anabolic/androgenic
steroid-induced aggression in hamsters. Pharmacol. Biochem. Behav. 85, 1–11.
doi: 10.1016/j.pbb.2006.06.022
Roberto, M., Cruz, M. T., Gilpin, N. W., Sabino, V., Schweitzer, P., Bajo, M., et al.
(2010). Corticotropin releasing factor-induced amygdala gamma-aminobutyric
Acid release plays a key role in alcohol dependence. Biol. Psychiatry 67, 831–839.
doi: 10.1016/j.biopsych.2009.11.007
Roberto, M., Madamba, S. G., Stouffer, D. G., Parsons, L. H., and Siggins,
G. R. (2004). Increased GABA release in the central amygdala of ethanol-
dependent rats. J. Neurosci. 24, 10159–10166. doi: 10.1523/JNEUROSCI.3004-
04.2004
Salas-Ramirez, K. Y., Montalto, P. R., and Sisk, C. L. (2010). Anabolic steroids have
long-lasting effects on male social behaviors. Behav. Brain Res. 208, 328–335.
doi: 10.1016/j.bbr.2009.11.026
Frontiers in Neuroscience | www.frontiersin.org 12 August 2015 | Volume 9 | Article 295
Mhillaj et al. Anabolic-androgens and brain reward
Sato, S. M., Johansen, J. A., Jordan, C. L., and Wood, R. I. (2010).
Membrane androgen receptors may mediate androgen reinforcement.
Psychoneuroendocrinology 35, 1063–1073. doi: 10.1016/j.psyneuen.2010.01.007
Sato, S. M., Schulz, K. M., Sisk, C. L., and Wood, R. I. (2008). Adolescents
and androgens, receptors and rewards. Horm. Behav. 53, 647–658. doi:
10.1016/j.yhbeh.2008.01.010
Schlussman, S. D., Zhou, Y., Johansson, P., Kiuru, A., Ho, A., Nyberg, F., et al.
(2000). Effects of the androgenic anabolic steroid, nandrolone decanoate,
on adrenocorticotropin hormone, corticosterone and proopiomelanocortin,
corticotropin releasing factor (CRF) and CRF receptor1 mRNA levels in the
hypothalamus, pituitary and amygdala of the rat. Neurosci. Lett. 284, 190–194.
doi: 10.1016/S0304-3940(00)01016-8
Schroeder, J. P., and Packard, M. G. (2000). Role of dopamine receptor subtypes in
the acquisition of a testosterone conditioned place preference in rats. Neurosci.
Lett. 282, 17–20. doi: 10.1016/S0304-3940(00)00839-9
Schwartzer, J. J., Ricci, L. A., and Melloni, R. H. Jr. (2009). Adolescent anabolic-
androgenic steroid exposure alters lateral anterior hypothalamic serotonin-2A
receptors in aggressive male hamsters. Behav. Brain Res. 199, 257–262. doi:
10.1016/j.bbr.2008.11.048
Shahidi, N. T. (2001). A review of the chemistry, biological action, and clinical
applications of anabolic-androgenic steroids. Clin. Ther. 23, 1355–1390. doi:
10.1016/S0149-2918(01)80114-4
Singh, R., Artaza, J. N., Taylor, W. E., Braga, M., Yuan, X., Gonzalez-Cadavid, N.
F., et al. (2006). Testosterone inhibits adipogenic differentiation in 3T3-L1 cells:
nuclear translocation of androgen receptor complex with beta-catenin and T-
cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic
transcription factors. Endocrinology 147, 141–154. doi: 10.1210/en.2004-1649
Singh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F., and Bhasin, S.
(2003). Androgens stimulate myogenic differentiation and inhibit adipogenesis
in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated
pathway. Endocrinology 144, 5081–5088. doi: 10.1210/en.2003-0741
Sinha-Hikim, I., Artaza, J., Woodhouse, L., Gonzalez-Cadavid, N., Singh, A. B.,
Lee, M. I., et al. (2002). Testosterone-induced increase in muscle size in
healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol.
Endocrinol. Metab. 283, E154–E164. doi: 10.1152/ajpendo.00502.2001
Sinha-Hikim, I., Roth, S. M., Lee, M. I., and Bhasin, S. (2003). Testosterone-
induced muscle hypertrophy is associated with an increase in satellite cell
number in healthy, young men. Am. J. Physiol. Endocrinol. Metab. 285,
E197–E205. doi: 10.1152/ajpendo.00370.2002
Spanagel, R., Herz, A., and Shippenberg, T. S. (1992). Opposing tonically active
endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
Proc. Natl. Acad. Sci. U.S.A. 89, 2046–2050. doi: 10.1073/pnas.89.6.2046
Steiner, H., and Gerfen, C. R. (1998). Role of dynorphin and enkephalin in the
regulation of striatal output pathways and behavior. Exp. Brain Res. 123, 60–76.
doi: 10.1007/s002210050545
Tamaki, T., Shiraishi, T., Takeda, H., Matsumiya, T., Roy, R. R., and Edgerton, V. R.
(2003). Nandrolone decanoate enhances hypothalamic biogenic amines in rats.
Med. Sci. Sports Exerc. 35, 32–38. doi: 10.1097/00005768-200301000-00006
Tanaka, K., Sakai, H., Hashizume, M., and Hirohata, T. (2000). Serum
testosterone:estradiol ratio and the development of hepatocellular carcinoma
among male cirrhotic patients. Cancer Res. 60, 5106–5110.
Tennant, F., Black, D. L., and Voy, R. O. (1988). Anabolic steroid
dependence with opioid-type features. N. Engl. J. Med. 319, 578. doi:
10.1056/NEJM198809013190910
Thevis, M., Sauer, M., Geyer, H., Sigmund, G., Mareck, U., and Schänzer,
W. (2008). Determination of the prevalence of anabolic steroids,
stimulants, and selected drugs subject to doping controls among elite
sport students using analytical chemistry. J. Sports Sci. 26, 1059–1065. doi:
10.1080/02640410801910293
Thiblin, I., Finn, A., Ross, S. B., and Stenfors, C. (1999a). Increased dopaminergic
and 5-hydroxytryptaminergic activities in male rat brain following long-term
treatment with anabolic androgenic steroids. Br. J. Pharmacol. 126, 1301–1306.
doi: 10.1038/sj.bjp.0702412
Thiblin, I., Lindquist, O., and Rajs, J. (2000). Cause and manner of death among
users of anabolic androgenic steroids. J. Forensic Sci. 45, 16–23.
Thiblin, I., Runeson, B., and Rajs, J. (1999b). Anabolic androgenic steroids and
suicide. Ann. Clin. Psychiatry 11, 223–231. doi: 10.3109/10401239909147074
Tremblay, M. S., Copeland, J. L., and Van Helder, W. (2004). Effect of training
status and exercise mode on endogenous steroid hormones in men. J. Appl.
Physiol. (1985) 96, 531–539. doi: 10.1152/japplphysiol.00656.2003
Triemstra, J. L., Sato, S. M., and Wood, R. I. (2008). Testosterone and nucleus
accumbens dopamine in the male Syrian hamster. Psychoneuroendocrinology
33, 386–394. doi: 10.1016/j.psyneuen.2007.12.006
Tucci, P., Morgese, M. G., Colaianna, M., Zotti, M., Schiavone, S.,
Cuomo, V., et al. (2012). Neurochemical consequence of steroid abuse:
stanozolol-induced monoaminergic changes. Steroids 77, 269–275. doi:
10.1016/j.steroids.2011.12.014
van der Vegt, B. J., Lieuwes, N., van de Wall, E. H., Kato, K., Moya-
Albiol, L., Martínez-Sanchis, S., et al. (2003). Activation of serotonergic
neurotransmission during the performance of aggressive behavior in rats.
Behav. Neurosci. 117, 667–674. doi: 10.1037/0735-7044.117.4.667
Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Ding, Y. S., Sedler,
M., et al. (2001a). Low level of brain dopamine D2 receptors in
methamphetamine abusers: association with metabolism in the orbitofrontal
cortex. Am. J. Psychiatry 158, 2015–2021. doi: 10.1176/appi.ajp.158.
12.2015
Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., et al.
(2001b). Loss of dopamine transporters in methamphetamine abusers recovers
with protracted abstinence. J. Neurosci. 21, 9414–9418.
Volkow, N. D., Fowler, J. S., Wolf, A. P., Schlyer, D., Shiue, C. Y., Alpert, R., et al.
(1990). Effects of chronic cocaine abuse on postsynaptic dopamine receptors.
Am. J. Psychiatry 147, 719–724. doi: 10.1176/ajp.147.6.719
Wichstrom, L., and Pedersen, W. (2001). Use of anabolic-androgenic steroids in
adolescence: winning, looking good or being bad? J. Stud. Alcohol 62, 5–13. doi:
10.15288/jsa.2001.62.5
Wines, J. D. Jr., Gruber, A. J., Pope, H. G. Jr., and Lukas, S. E. (1999). Nalbuphine
hydrochloride dependence in anabolic steroid users. Am. J. Addict. 8, 161–164.
doi: 10.1080/105504999305965
Wood, R. I. (2002). Oral testosterone self-administration in male hamsters: dose-
response, voluntary exercise, and individual differences. Horm. Behav. 41,
247–258. doi: 10.1006/hbeh.2002.1769
Wood, R. I. (2004). Reinforcing aspects of androgens. Physiol. Behav. 83, 279–289.
doi: 10.1016/j.physbeh.2004.08.012
Wood, R. I. (2008). Anabolic-androgenic steroid dependence? Insights
from animals and humans. Front. Neuroendocrinol. 29, 490–506. doi:
10.1016/j.yfrne.2007.12.002
Wood, R. I., Johnson, L. R., Chu, L., Schad, C., and Self, D.W. (2004). Testosterone
reinforcement: intravenous and intracerebroventricular self-administration
in male rats and hamsters. Psychopharmacology (Berl) 171, 298–305. doi:
10.1007/s00213-003-1587-7
Yates, W. (2000). Testosterone in psychiatry. Arch. Gen. Psychiatry 57, 155–156.
doi: 10.1001/archpsyc.57.2.155
Yates, W. R., Perry, P. J., and Andersen, K. H. (1990). Illicit anabolic steroid
use: a controlled personality study. Acta Psychiatry Scand. 81, 548–550. doi:
10.1111/j.1600-0447.1990.tb05496.x
Yesalis, C. E., Bahrke, M. S., Kopstein, A. N., and Barsukiewicz, C. K. (2000).
“Incidence of anabolic steroids use: a discussion of methodological issues,”
in Anabolic Steroids in Sport and Exercise, 2nd Edn., ed C. E. Yesalis
(Champaign, IL: Human Kinetics), 73–115.
Zotti, M., Tucci, P., Colaianna, M., Morgese, M. G., Mhillaj, E., Schiavone, S., et al.
(2014). Chronic nandrolone administration induces dysfunction of the reward
pathway in rats. Steroids 79, 7–13. doi: 10.1016/j.steroids.2013.10.005
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Mhillaj, Morgese, Tucci, Bove, Schiavone and Trabace. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 13 August 2015 | Volume 9 | Article 295
